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A B S T R A C T
Chondrosarcomas are malignant cartilage tumors that are relatively resistant towards conventional therapeutic
approaches. Kinase inhibitors have been investigated and shown successful for several different cancer types. In
this study we aimed at identifying kinase inhibitors that inhibit the survival of chondrosarcoma cells and thereby
serve as new potential therapeutic strategies to treat chondrosarcoma patients.
An siRNA screen targeting 779 different kinases was conducted in JJ012 chondrosarcoma cells in parallel
with a compound screen consisting of 273 kinase inhibitors in JJ012, SW1353 and CH2879 chondrosarcoma cell
lines. AURKA, CHK1 and PLK1 were identified as most promising targets and validated further in a more
comprehensive panel of chondrosarcoma cell lines. Dose response curves were performed using tyrosine kinase
inhibitors: MK-5108 (AURKA), LY2603618 (CHK1) and Volasertib (PLK1) using viability assays and cell cycle
analysis. Apoptosis was measured at 24 h after treatment using a caspase 3/7 assay. Finally, chondrosarcoma
patient samples (N = =34) were used to examine the correlation between AURKA, CHK1 and PLK1 RNA
expression and documented patient survival.
Dose dependent decreases in viability were observed in chondrosarcoma cell lines after treatment with MK-
5108, LY2603618 and volasertib, with cell lines showing highest sensitivity to PLK1 inhibition. In addition
increased sensitivity to conventional chemotherapy was observed after CHK1 inhibition in a subset of the cell
lines. Interestingly, whereas AURKA and CHK1 were both expressed in chondrosarcoma patient samples, PLK1
expression was found to be low compared to normal cartilage. Analysis of patient samples revealed that high
CHK1 RNA expression correlated with a worse overall survival.
AURKA, CHK1 and PLK1 are identified as important survival genes in chondrosarcoma cell lines. Although
further research is needed to validate these findings, inhibiting CHK1 seems to be the most promising potential
therapeutic target for patients with chondrosarcoma.
1. Introduction
Chondrosarcomas account for 20% of primary bone tumors and are
characterized by malignant cartilage producing cells [1]. Depending on
the morphology and the location, chondrosarcoma can be subdivided
into conventional chondrosarcoma and more rare subtypes; dediffer-
entiated chondrosarcoma, mesenchymal chondrosarcoma, clear cell
chondrosarcoma and periosteal chondrosarcoma. Conventional chon-
drosarcoma accounts for 85% of all chondrosarcoma cases [1] and is
further classified into central chondrosarcoma, located in the medulla
of the bone, and peripheral chondrosarcoma, found at the surface of the
bone [2]. These two different conventional chondrosarcoma subtypes
show the same histological features: however a distinct molecular
background is observed [1]. Conventional chondrosarcoma is classified
into three different grades, which is the most important prognostic
factor. Atypical cartilaginous tumors (ACT)/chondrosarcoma grade I
show a low cellularity, a large amount of cartilage matrix, rarely me-
tastasize, and have a relatively good prognosis. Grade II and grade III
chondrosarcomas behave more aggressive and show a more cellular
histology with reduced cartilage matrix and a poor prognosis. Patients
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with grade II chondrosarcomas show 64% overall survival and patients
with grade III chondrosarcomas show a very poor 10 years overall
survival of only 29% [1,2]. As chondrosarcomas are resistant to con-
ventional radio- and chemotherapy, the only treatment option to date
for patients with chondrosarcoma is surgical removal. This is a major
problem especially for patients with tumors in inoperable locations and
patients with metastatic disease [2].
Protein kinases are important for cellular processes and are often
found deregulated in cancer [3]. Kinome profiling in chondrosarcoma
cell cultures previously revealed that the AKT, Src and Ras/Raf/MEK
pathways were most active in chondrosarcoma [4]. In addition, Src
kinases were shown to be important for chemoresistance, as shown by
sensitization for doxorubicin upon inhibition with dasatinib, as well as
a high expression of Src kinase family members in chondrosarcoma
patient tissues [5]. Using phospho-RTK arrays the phosphorylation
status of 42 RTKs was investigated in chondrosarcoma cell lines, which
led to the observation of a heterogeneous RTK activation pattern in
these cells. P-S6 activation was found in 69% of conventional
Fig. 1. siRNA screen and compound screen identify PLK1, AURKA and CHK1 as potentially important kinases for survival of chondrosarcoma cells. A. Set-up of siRNA
screen. Primary screening was performed on 779 SMARTpools targeting kinases and kinase related genes. The secondary screen was performed in JJ012 and CH2879
cells and consisted of 35 SMARTpool siRNAs identified in the primary screen (decreased cell proliferation below 20% compared to mock conditions). Deconvolution
consisted of 4 separate siRNAs and the SMARTpool targeting 9 different genes. B. Hoechst area as a percentage to mock for JJ012 cells. Each dot represents one
SMARTpool targeting one Kinase or kinase related gene. Duplicates are shown for each gene and only when both screens showed a percentage below 20% it was
considered as a hit. C. Kinases that showed cell killing in both JJ012 and CH2879 were selected for deconvolution (AURKA, CHK1, CNKSR1, COPB2, EPHA6, IRAK3,
STK39, TRAT1, PLK1). D. Deconvolution results in JJ012 and CH2879 cells showing that AURKA, CHK1, COPB2, CNKSR1 and PLK1 are important for cell survival in
both cell lines. E. Compound screen results in JJ012, CH2879 and SW1353 showing 35 hits in common in the top 50 compounds in each cell line. In addition, 8
compounds were found in JJ012 and CH2879, 6 in JJ012 and SW1353 and 2 in CH2879 and SW1353. F. Compounds that were identified in all three or two out of
three cell lines were selected and showed that Aurora kinase, Pi3K-mTOR, mTOR, PLK, CDK and multi-target comprised the largest groups. In addition, compounds
targeting c-MET, ALK, SRC, SYK, JAK, IKK and CHK were identified.
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chondrosarcoma and 44% of dedifferentiated chondrosarcoma in-
dicating that the downstream PI3K/mTOR pathway might be an im-
portant therapeutic target [6]. Furthermore, we previously showed a
role for mTORC1 and C2 as an important regulator of chondrosarcoma
metabolism [7].
To further unravel the role of kinases in chondrosarcoma we chose a
screening-based approach using siRNAs targeting 779 different kinases
and kinase related genes. In addition a compound screen was performed
consisting of 273 compounds targeting kinases implicated in survival
pathways often deregulated in cancer. By comparing the hits we aim at
identifying kinase regulated pathways that are important for chon-
drosarcoma survival.
2. Material and methods
2.1. Cell culture
Conventional chondrosarcoma cell lines SW1353 (ATCC), JJ012
[8], CH2879 [9], CH3573 [10] and L835, and dedifferentiated chon-
drosarcoma cell lines L3252B, L2975 [11] and NDCS1 [12] were cul-
tured in RPMI-1640 (Gibco, Invitrogen Life-Technologies, Scotland,
UK) supplemented with 10 or 20% Fetal Calf Serum (Gibco, Invitrogen
Life-Technologies, Scotland, UK). Mesenchymal chondrosarcoma cell
line MCS170 [13] was cultured in IMDM medium (Gibco, Invitrogen
Life-Technologies, Scotland, UK) supplemented with 15% fetal Calf
Serum. All cell lines were cultured at 37 °C in a humidified incubator
(5% CO₂). Identity of cell lines was confirmed using the Cell ID Gene
Print 10 system (Promega Benelux BV, Leiden, The Netherlands) before
and after completion of the experiments. Mycoplasma tests were per-
formed on a regular basis.
2.2. Compounds
MK-5108 (S2770), LY2603618 (S2626), Volasertib (S2235) and
ABT-737 (S1002) (positive control apoptosis assay) were purchased
from Selleckchem and dissolved in DMSO to a working stock of 10 mM
according to the manufacturer's instructions. Z-VAD-FMK was obtained
from BD biosciences (550377). Doxorubicin and Cisplatin were ob-
tained in a solution of 0.9% NaCl from the inhouse pharmacy of the
Leiden University Medical Centre.
2.3. siRNA screen
To identify critical genes for chondrosarcoma cell survival, a fo-
cused targeted siRNA screen was performed on the JJ012 central
chondrosarcoma cell line targeting kinases and kinase related genes
(Dharmacon, GE life sciences, Landsmeer, the Netherlands, G-003505).
Hits were selected for further validation, when both duplicates showed
a reduction in cell numbers of 80% or more. A secondary screen in-
cluding 35 most promising hits was performed in JJ012 and CH2879
chondrosarcoma cell lines (Fig. 1A). Reverse transfection was per-
formed using SMARTpools of 4 different siRNAs targeting the same
gene in a final concentration of 50 nM DharmaFECT 3 (Thermo Fisher
Scientific Inc. Waltham, MA USA, T-2003) was used as a transfection
reagent according to the manufacturer's instructions. Deconvolution
confirmation screens, including 9 hits identified in both cell lines were
performed on JJ012 and CH2879 cells where each of the four in-
dividual siRNAs was transfected separately. A gene was considered as a
hit when three out of four individual siRNAs mimicked the SMARTpool
in both cell lines or when one cell line showed at least three out of four
the other at least two out of four siRNAs mimicking the SMARTpool.
Mock (no siRNA), GFP, and GAPDH siRNAs were used as a negative
control and KIF11 siRNA as a positive control. Transfection was per-
formed using 7000 cells/well for JJ012 and 10,000 cells/well for
CH2879 cells in µ-clear 96 well black clear bottom plates (Corning B.V.
Life Sciences, Amsterdam, the Netherlands). 24 h after transfection the
medium was replaced with medium containing either 1 µM doxor-
ubicin, 5 µM cisplatin or PBS and after five days cells were fixed with
formalin and stained with Hoechst. Imaging was performed using a BD-
pathway microscope. To quantify the amount of nuclei the total
Hoechst area was determined using Image Pro analyzer software and
normalized to mock treated cells as described previously [14].
2.4. Compound screen
A compound screen was performed in JJ012, SW1353 and CH2879
cells using a kinase library from Selleckchem (2014, L1200) containing
273 compounds targeting different pathways. SW1353 and JJ012 were
plated at an optimal density of 5000 cells/well and CH2879 cells were
plated at a density of 7000 cells/well. The screen was performed in
duplicate in µ-clear 96 well black clear bottom plates (Corning B.V. Life
Sciences, Amsterdam, the Netherlands). After overnight attachment of
the cells, compounds were added in a concentration of 1 µM as single
treatment or in combination with 0.05 µM doxorubicin or 0.8 µM cis-
platin. A high concentration of doxorubicin (5 µM) was used as a po-
sitive control. After 72 h of incubation cell viability was assessed using
Presto Blue viability reagent (see next paragraph).
2.5. Viability assay
Optimal cell amounts for each cell line were seeded in triplicate in
96-well plates. After 24 h, increasing concentrations from 0 to 1000 nM
of MK-5108 and Volasertib or 0–1250 nM LY2603618 were added to
the appropriate wells and cells were incubated for an additional 72 h.
After the incubation period, a Presto Blue assay (Thermo Fisher
Scientific Inc. Waltham, MA USA, A13262) was carried out according to
the manufacturer's instructions. After 1 h, viability results were mea-
sured by fluorescence at 590 nm on a fluorometer (Victor3V, 1420
multilabel counter, Perkin-Elmer, Groningen, the Netherlands). All ex-
periments were performed in triplicate at least 3 times.
2.6. RNA isolation and quantitative real time PCR
RNA was isolated from fresh frozen tissue of 34 conventional
chondrosarcoma primary tumor tissues and six cartilage control tissues:
three growth plates, and three articular cartilage tissues
(Supplementary Table 1). RNA was isolated using TRIzol (Invitrogen,
Carlsbad CA) followed by RNA clean up using the RNeasy mini kit
(Qiagen) according to the manufacturer's instructions. All samples were
handled as approved by the LUMC ethical board (B17.021). AURKA,
CHK1 and PLK1 expression was normalized towards housekeeping
genes PPIA and CPSF6 as previously described [15]. Primer pairs are
described in supplementary Table 2.
2.7. Cell cycle analysis
Optimal cell amounts for each cell line were seeded in 6-well plates
and allowed to attach overnight. Cells were treated with IC50 con-
centrations of LY2603618, MK-5108 or Volasertib. After 24 h, cells
were stained with Solution 18 Ao-DAPI (Catalog no. 910-3018,
Chemometec, Denmark) according to the manufacturer's instructions
and cells were counted using an automated cell analyzer
(NucleoCounter NC-250, Chemometec, Denmark). Remaining cells
were centrifuged for 5 min at 500 g at 4 °C. Supernatant was removed
and the cells were washed with PBS (B. BraunMelsungen AG,
Melsungen, Germany). Methanol fixation was carried out, after which
cells were washed with PBS/Tw 0.05%. The samples were centrifuged
using the same settings and were then washed with PBA/Tw 0.05%
(PBS/1.0% BSA/Tw 0.05%). After the final centrifugation of the cells,
cells were stained with10 µM DAPI in PBA/Tw 0.05%. The cells were
stored at 4° and analysis was carried out next day using the NC-250
nucleoCounter. Results were analyzed using, Winlist 3D and ModFit LT
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software (Verity software house). Five biological replicates were in-
cluded for each sample.
2.8. Apoptosis assay
The caspase glo 3/7 assay (Promega, Madison, WI, USA) was used to
detect apoptosis, according to the manufacturer's instructions. Cells
were plated in a white 96-well plate and treated the next day with IC50
concentrations (obtained from dose response curves) of MK-5108,
LY2603618, Volasertib for 24 h. ABT-737 and Doxorubicin were added
to the cells as a positive control. Z-vad-FMK, a caspase inhibitor was
used as a positive control. After treatment period, caspase glo 3/7 assay
was added to cells, which were incubated for an additional 30 min at
room temperature. Caspase activity was measured by luminescence
using a luminometer (Victor3V, 1420 multilabel counter, Perkin-Elmer)
according to the manufacturer's instructions. Experiments were per-
formed three times in duplicate.
2.9. Western blotting
Protein expression of Chk1 (Cell signaling technology #2360) and
p-Chk1(S345) (Cell signaling technology, #2348) was determined in
JJ012, SW1353 and CH2879 in control conditions and after treatment
for 2 or 24 h with IC50 concentrations of LY2603618 (JJ012 1 µM,
SW1353 441 nM, CH2879 449 nM). In addition PARP cleavage (Cell
signaling technology #9532) was assessed after treatment of JJ012,
SW1353 and CH2879 for 2 or 24 h with IC50 concentrations of MK-
5108, LY2603618 or Volastertib (MK-5108; SW1353: 1 µM, JJ012:
513 nM, CH2879: 847 nM, Volasertib: SW1353: 34 nM, JJ012 11 nM,
CH2879: 24 nM, LY2603618 as described above). Lysates were ob-
tained of cells grown until 70% confluence using hot-SDS buffer (1%
SDS, 10 mM Tris/EDTA with complete inhibitor (Roche
#11697498001) and phosSTOP (Roche #04906837001) as previously
described [4]. Expression of gapdh (Cell signaling technology #5174)
was determined as a loading control. A total of 10 µg was loaded on the
gel for each sample and blocking was performed using 5% milk. Pri-
mary antibodies were diluted in 5% BSA (bovine serum albumin) and
incubated overnight. Blotting was performed on PVDF membranes and
detection was done using enhanced chemo-luminescence (west Pico
Plus chemiluminescent Substrate, Thermo Fisher Scientific, Waltham,
MA, USA) followed by visualization using the ChemiDoc imaging
system of Biorad.
2.10. Statistical analysis
Dose response curves and IC50 values were determined using Prism
7 GraphPad software. Statistically significant differences were assessed
by performing a 2-way ANOVA test, correcting for multiple compar-
isons using Turkey's test. To assess synergy access over Bliss was cal-
culated and percentages above 12 were considered as synergistic
[16,17]. Overall survival was determined using SPSS software by per-
forming a Kaplan Meyer analysis and assessing significance using a
Mantel Cox Log Rank test.
3. Results
3.1. siRNA screen identifies PLK1, AURKA, COPB2, CHEK1, and CNKSR1
as most important survival genes in chondrosarcoma cells
A siRNA screen targeting 779 kinases and kinase related genes
identified 35 genes that decreased survival of JJ012 chondrosarcoma
cells more than 80% upon inhibition in both duplicate measurements
(see Fig. 1A and B and supplementary Table 3). No siRNAs were
identified that could sensitize JJ012 cells to doxorubicin or cisplatin.
Transfection with control GFP siRNAs led to a slight reduction in cell
amounts compared to mock conditions in most plates, however
silencing of GAPDH led to a large reduction in cell amounts, indicating
that this cannot be used as a control for CS siRNA screens (supple-
mentary figure 1). Knock down of KIF11 led to a strong reduction in cell
amounts, indicating successful knock down in all plates except plate 7
which was treated with doxorubicin or cisplatin. This did not influence
the hit selection process. A second validation screen was performed in
JJ012 and CH2879 cell lines including the 35 most promising siRNAs to
select genes important for both cell lines. This reduced the number of
candidates to eight that were found in both JJ012 and CH2879 cells
(Fig. 1C). The remaining 19 targets, from the first JJ012 screen, could
not be reproduced/identified in JJ012 and were absent as well in
CH2879 cells. The eight hits identified in both JJ012 and CH2879 were
selected for deconvolution and PLK1, AURKA, CHK1, COPB2 and
CNKSR1 were confirmed (Fig. 1D).
3.2. Compound screening identifies cell cycle regulators as most promising
targets in chondrosarcoma cell lines
In parallel with the siRNA screen a compound screen including 273
compounds targeting kinases and kinase related pathways was per-
formed in three different chondrosarcoma cell lines. The top 50 com-
pounds, that showed the highest reduction in cell numbers as compared
to DMSO treated controls, of each cell line were compared and 34
compounds were found to be effective in all three cell lines (Fig. 1E),
while in total 48 compounds were shared between at least 2 cell lines.
The percentage of compounds targeting a specific pathway as compared
to the total of 48 hit compounds are represented in Fig. 1F. Inhibitors of
cell cycle regulators Aurora kinases (13/16), Polo like kinases (5/5) and
Cyclin dependent kinases (4/12)represent a substantial portion
(Fig. 1F), confirming the findings of the siRNA screen. Also, inhibitors
of the Pi3K and mTOR pathway (12/25) are one of the major hits.
Furthermore, inhibitors of cMET (2/13), ALK (1/2), SRC (1/3), SYK (1/
5), JAK (1/13), IKK (1/2) and CHK (1/3) are also represented (see
supplementary Table 4 for a list of selected compounds). Similar to the
siRNA screen, no pathways were identified that upon inhibition clearly
sensitized for either doxorubicin or cisplatin (supplementary Table 5).
Based on the overlap between the siRNA and the kinase inhibitor screen
we chose to continue with PLK1, AURKA and CHK1 as most promising
targets. In addition, previous studies already showed that mTOR, CDK
and Src are important therapeutic targets for patients or subsets of
patients with chondrosarcoma [4,18,19].
3.3. Inhibition of AURKA, CHK1 and PLK1 in chondrosarcoma cells results
in a dose dependent decrease in viability, which is not related to RNA
expression levels
Dose dependent decreases in viability were observed when different
chondrosarcoma cell lines were treated with inhibitors for AURKA (MK-
5108), CHK1 (LY2603618) or PLK1 (Volasertib) (Fig. 2A). Lowest IC50
values were obtained when cell lines were treated with PLK1 inhibitor
volasertib, however treatment with CHK1 inhibitor LY2603618 also led
to low IC50 values (see Table 1). These values have previously been
shown as clinically achievable in human plasma in phase I and phase II
trials [20–22]. L835, L3252 and MCS170, which are slower growing
TP53 wildtype cell lines showed higher IC50 values for all compounds
compared to the other faster growing cell lines. RNA expression ana-
lysis showed a variable expression pattern of AURKA, CHK1 and PLK1
across the cell lines, with highest expression of all three in CH2879
(Fig. 2B). Only few cell lines responded to inhibition of AURKA, which
was not correlated to the level of AURKA expression. Likewise, no
correlation was observed between sensitivity to CHK1 inhibition and
CHK1 expression levels. Interestingly, of the three lines showing low
PLK1 expression, L835 and MCS-170 showed a poor response to PLK1
inhibition, whereas L2975 exhibited a response, which although PLK1
expression was lower, still resembled the response patterns of high
PLK1 expressors, but never reached 0% cell viability. Combination
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treatment with doxorubicin or cisplatin and MK-5108 and LY2603618
was performed in three conventional chondrosarcoma cell lines and
results showed a synergistic effect between doxorubicin and cisplatin
with the CHK1 inhibitor LY2603618 in JJ012 and SW1353 cell lines as
shown by more than 12% increase in Excess over Bliss score (Fig. 2C).
This shows that chondrosarcoma cells are more sensitive towards
treatment with chemotherapy when CHK1 is inhibited. Increased
phosphorylation of CHK1 on Ser345 was observed after treatment with
LY2603618 in JJ012, SW1353 and CH2879, indicating that inhibiting
CHK1 under these conditions leads to activation of ATM/ATR (Fig. 2D).
No basic CHK1 phosphorylation was observed on Ser345.
3.4. Cell cycle analysis reveals a block in G2 after AURKA inhibition
Cell cycle analysis was carried out after 24 h of treatment with MK-
5108, LY2603618 or Volasertib and showed that inhibition of AURKA
with MK-5108 caused a block in G2/M in both JJ012 (p < 0.0001) and
CH2879 (p < 0.0001) cell lines (Fig. 3A, Supplementary figure 2).
Fig.. 2. Chondrosarcoma cell lines are sensitive for compounds targeting AURKA, CHK1 and PLK1. A. Dose response curves showing viability measured after 72 h
using presto blue viability reagent for 9 chondrosarcoma cell lines targeting AURKA (MK-5108), CHK1 (LY2603618) or PLK1 (volasertib). The top three panels
represent the conventional chondrosarcoma cell lines and the bottom panel the rare chondrosarcoma cell lines including three dedifferentiated cell lines (L2975,
L3252 and NDCS1) and one mesenchymal chondrosarcoma cell line (MCS-170). Highest sensitivity is observed after inhibition with Volasertib. Experiments were
performed in triplicate at least three times. B. RNA expression in chondrosarcoma cell lines for AURKA, CHK1 and PLK1. No correlation between expression and
sensitivity for the different inhibitors is observed. C. Excess over Bliss percentages of combination treatment of 100 nM LY2603618 and doxorubicin (DXR) or
cisplatin (CDDP) showing that JJ012 and SW1353 can be sensitized to conventional chemotherapy after Chk1 inhibition. D. Western blot showing CHK1 and P-CHK1
(S345) expression after treatment for 2 or 24 h with IC50 concentrations of LY2603618. Gapdh expression is assessed as a loading control. Hela cells treated with
Hydroxyurea have been used as a positive control for p-CHK1 expression.
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Treatment with CHK1 inhibitor LY2603618 did result in an increase in
S-phase (p==0.0003) and debris (p==0.0004) in JJ012, but not in
CH2879. Thus, while inhibiting AURKA clearly showed a G2/M arrest
in both cell lines, only JJ012 showed a clear S-phase arrest after CHK1
inhibition. To assess whether this cell cycle arrest led to apoptotic cell
death, caspase 3/7 dependent apoptosis was evaluated after 24 h of
treatment with MK-5108, LY2603618 or Volasertib (Fig. 3B). Results
were variable, but small increases were observed after treatment with
MK-5108 or Volasertib in SW1353. PARP cleavage was assessed to
determine general cell death and showed a small amount of PARP
cleavage, especially in MK-5108 treated JJ012 and CH2879 cells, but
no clear differences were observed (Fig. 3C). These results indicate that
even though the cell cycle inhibitors successfully caused cell cycle ar-
rest in both cell lines, this did not directly lead to an increase in cell
death after 24 h.
3.5. High CHK1 RNA expression in chondrosarcoma tissue samples is
correlated with a worse overall survival
Expression of AURKA, CHK1 and PLK1 was investigated in a panel
of chondrosarcoma tissue samples and revealed that both AURKA and
CHK1 showed higher RNA expression compared to cartilage in a subset
of chondrosarcoma patients (Fig. 4A). PLK1 expression was lower
compared to normal cartilage in all samples tested, but high in chon-
drosarcoma cell lines. Most samples that showed higher AURKA or
CHK1 expression compared to normal cartilage were in the high-grade
group, but this was not significantly different. Samples were divided
Table 1
IC50 values and 95% confidence intervals for nine different chondrosarcoma
cell lines treated with inhibitors for AURKA (MK-5108), CHK1 (LY2603618) or
PLK1 (Volasertib).
MK-5108 LY2603618 Volasertib
JJ012 513.4 (464.2–570.1) > 1000 10.98 (10.31–11.73)
SW1353 >1000 441.2 (386.6–502.8) 33.67 (31.76–35.66)
CH2879 847.6 (723.3–109) 449.3 (401–04.6) 24.28 (20.69–28.18)
CH3573 >1000 815.2 (730.2–918.40 8.3829 (7.083–9.809)
L835 >1000 >1000 >1000
L2975 520.8 (440.5–631) 826.1 (781.3–875.8) 11.33 (9.109–13.92)
Ndcsi > 1000 442.6 (420.5–465.8) 3.166 (2.54–4.003)
L3252 >1000 >1000 252.4 (187.1–363.9)
MCS170 >1000 >1000 276.1 (181.2–482)
Fig.. 3. Cell cycle and cell death analysis after AURKA, CHK1 or PLK1 inhibition. A. Cell cycle analysis after 24 h of treatment with MK-5108, LY2603618 or
Volasertib in JJ012 or CH2879 cells. Both cell lines show a decrease in G1 and an increase in G2 phase after treatment with MK-5108. In addition, CH2879 cells show
a decrease in S phase after treatment with MK-5108. JJ012 cells show a decrease in G1 after inhibition with either MK-5108, LY2603618 or Volasertib and an
increase in S-phase and debris after LY2603618 treatment. B. Apoptosis induction measured using the caspase-glo 3/7 kit in JJ012, CH2879 and SW1353 after
treatment for 24 h with IC50 concentrations of MK5108, LY2603618 or Volasertib. Z-vad was added as a control. Only the positive control showed significant caspase
induction in all cell lines. SW1353 showed significant upregulated caspase activity after treatment with MK-5108 and Volasertib compared to dmso treated controls.
For both cell cycle and apoptosis experiments mean values are shown of three experiments performed in duplicate. P-values were calculated using a 2way ANOVA
test, correcting for multiple comparisons using Tukeys test. C PARP cleavage assessed after 24 h of treatment using IC50 concentrations of MK-5108, LY2603618 and
Volasertib. As a positive control CH2879 cells treated with the combination of ABT-737 and doxorubicin has been taken along.
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into high and low expression based on expression compared to normal
cartilage (> 1=high expression,< 1=low expression) and survival
analysis was performed (Fig. 4B). No significant difference in survival
was observed between low or high expression of AURKA (p==0.131),
but high CHK1 expression was significantly correlated with a worse
overall survival compared to low CHK1 expression (p = =0.018).
These results show that CHK1 expression is correlated towards a poor
prognosis in chondrosarcoma patients.
4. Discussion
Chondrosarcoma patients suffer from limited treatment options due
to relative chemo- and radio resistance. In this study we sought to
identify new targetable pathways in chondrosarcoma cells by per-
forming a kinase focused siRNA and compound screen. By comparing
the hits that were identified in both screens we identified AURKA, PLK1
and CHK1 as important survival regulators in chondrosarcoma cells.
AURKA, PLK1 and CHK1 are all involved in cell cycle regulation and
often deregulated in cancer cells [23].
Previous studies in chondrosarcoma already revealed that Src ki-
nases could be a potential therapeutic target in chondrosarcoma [5]. In
addition mTOR was shown to be active in a large portion of chon-
drosarcoma patient samples, as well as an important regulator of
chondrosarcoma metabolism [6,7]. These hits were also confirmed in
our compound screen data.
Cell cycle progression is tightly regulated and controlled by cyclin
dependent kinases (CDKs). Activity of CDKs is induced by mitogenic
signals but can be inhibited by cell cycle checkpoints in response to
DNA damage. Proteins that function in regulating the cell cycle are
often deregulated in cancer and can function as possible therapeutic
targets as mono therapy or combination with chemotherapy [24]. In
this study we show a possible role for targeting the cell cycle in chon-
drosarcoma.
AURKA and PLK1 are involved in G2 to M phase progression and are
essential during mitosis and cytokinesis. AURKA phosphorylates PLK1
to activate Cyclin B-CDK1 complexes leading to progression from G2 to
M-phase. During mitosis AURKA and PLK1 form several complexes with
other proteins that regulate the maturation and separation of centro-
somes and the assembly of the bipolar spindle. Furthermore PLK1 is a
member of the chromosomal passenger complex (CPC) that regulates
chromosome dynamics and cohesion, kinetochore microtubule attach-
ments, spindle assembly checkpoint and cytokinesis [25]. Over-
expression of both AURKA and PLK1 has been shown in a variety of
different tumors [26,27].
A subset of chondrosarcoma cell lines showed a dose dependent
decrease in viability after inhibiting AURKA using MK-5108, which was
not related towards AURKA RNA expression. A clear block in G2/M
phase of the cell cycle was observed after 24 h of treatment with MK-
Fig. 4. Gene expression analysis shows that high expression of CHK1 is correlated to a worse survival in chondrosarcoma patients. A.RNA expression of AURKA,
CHK1 and PLK1 in chondrosarcoma patient samples and chondrosarcoma cell lines compared to expression in normal articular cartilage samples. Each dot represents
one sample. B. Kaplan Meyer analysis of patient samples with low and high expression of AURKA and CHK1. High CHK1 expression shows a significant correlation
with a worse overall survival in chondrosarcoma patients. Samples with< 1 expression were considered as ‘low’ expression and samples> 1 expression were
considered as high expression. P values were calculated using a mantel cox log rank test.
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5108. We did not find any correlation between expression of AURKA
and survival, in contrast to a study from 2012 by Liang et al. in which
they showed a correlation between high AURKA expression and a worse
overall survival in chondrosarcoma patients [28]. A clinical study in-
cluding 6 chondrosarcoma patients investigating the efficacy of Aurora
Kinase A inhibition using Alisertib showed a partial response in one
patient with dedifferentiated chondrosarcoma [29]. However a phase
III study in lymphoma was discontinued because of lack of response
compared to the other study arm [30]. Different studies testing com-
bination strategies show different adverse effects and maximum toler-
ated dose, which indicates that results might vary between tumor types
and patients [21,31–33]. Recently AURKA inhibitors have been iden-
tified as synthetic lethal with defective RB1 [34]. In chondrosarcoma
33% of tumors show a defect in the RB1 pathway [35], meaning that in
these tumors treatment with AURKA inhibitors might be good treat-
ment option.
Chondrosarcoma cell lines were sensitive for inhibition of PLK1
using Volasertib, but no clear cell cycle effects were observed after 24 h
of treatment. This is surprising because PLK1, just like AURKA, is im-
portant for entry in M-phase, although multiple other non-cell cycle
related functions have been proposed as well, for example PLK1 can
regulate mTORC1 activity [36,37]. This can influence the effects that
we detect on the cell cycle. Expression of PLK1 in chondrosarcoma
tissue samples was low, indicating that targeting PLK1 might not be a
good therapeutic strategy for chondrosarcoma patients.
CHK1 is activated by ATM or ATR after the occurrence of DNA
damage. Its activation will cause the cell to halt cell proliferation in S or
G2 and allows the cell to repair DNA damage. When CHK1 is inhibited
DNA damage will accumulate and the cell will die during mitosis. Like
AURKA and PLK1, CHK1 is also overexpressed in different types of
cancer. Like AURKA and PLK1, CHK1 is also overexpressed in different
types of cancer. Using LY2603618 CHK1 was inhibited in a panel of
chondrosarcoma cell lines, which resulted in an increased phosphor-
ylation of CHK1 at position S345, which is in agreement with previous
reports [38]. Possibly single CHK1 inhibition already leads to activation
of the DNA damage response, and IC50 concentrations are not high
enough to completely prevent phosphorylation by ATM/ATR. A subset
of chondrosarcoma cell lines was responding to the treatment, and an
increase in S phase was observed in JJ012 cells, but not in CH2879 cells
treated with LY2603618. In addition, JJ012 and SW1353 could be
sensitized for chemotherapy using CHK1 inhibition. Previous studies
already showed the importance of CHK1 in Ewing, Osteo- and soft
tissue sarcomas [39–41] and its use in single and combination treat-
ment in pre-clinical models. In addition, we also found a correlation
between overall survival and CHK1 RNA expression in chondrosarcoma
patient tissues, indicating that more aggressive chondrosarcomas show
higher expression of CHK1. Second generation CHK1 inhibitors,
showing less toxicity compared to first generation inhibitors are cur-
rently tested in the clinic in combination with chemotherapy in ad-
vanced cancers [42–44].
Cells with defective P53 protein function have been shown to be
more sensitive to inhibitors for CHK1 [45] as well as AURKA and PLK1
compared to cells with intact P53 [46,47]. Inactivation of P53 will lead
to a compromised G1 checkpoint, which makes mutated cells more
dependent on the G2 checkpoint to be able to repair DNA damage. In
our study we do observe a difference in sensitivity between TP53
wildtype and TP53 mutant chondrosarcoma cell lines; cell lines with
intact P53 are less sensitive to inhibition of AURKA, CHK1 or PLK1.
However, these cells also grow slower compared to the other cell lines,
which could confound the observed difference in response. Mutations in
TP53 have been observed in 20% of chondrosarcomas [35], indicating
that inhibitors of cell cycle regulators might be of interest especially for
these patients.
In conclusion, we performed a kinase focused siRNA and compound
screen and identified cell cycle regulators AURKA, CHK1 and PLK1 as
interesting targetable proteins for follow up studies. RNA expression
analysis revealed expression of AURKA and CHK1 in a subset of chon-
drosarcoma patients, while PLK1 expression was minimal, compared to
normal cartilage tissue. In addition high CHK1 expression was corre-
lated towards a decrease in survival time. Also inhibition of CHK1 could
sensitize a subset of chondrosarcoma cells towards chemotherapy.
Future studies should determine the role of cell cycle proteins in
chondrosarcoma, however based on our results CHK1 seems to be a
promising therapeutic candidate for patients with (TP53 mutated)
chondrosarcoma, especially in combination strategies.
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